Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-09-13FDA Approved: TIMOLOL MALEATE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved Ingenus Pharmaceuticals' original ANDA for Timolol Maleate ophthalmic solution, sanctioning a generic treatment option for open…
-
FDA approval · 2022-09-07FDA Approved: TIMOLOL MALEATE — Original Application (Micro Labs Limited)
FDA approved timolol maleate from Micro Labs Limited under an original application (ANDA) for lowering intraocular pressure in open-angle gl…
-
CLINICAL_TRIALS trial_result · 2022-08-10Clinical Trial Update: Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. [Phase 3]
Phase 3 bioequivalence study with clinical endpoint comparing bimatoprost ophthalmic solution 0.01% to LUMIGAN in chronic open-angle glaucom…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension [Phase 1, Phase 2]
A safety, tolerability, and efficacy study (Phase 1/2) of FM101 in patients with ocular hypertension is ongoing, with status currently unkno…
-
FDA approval · 2022-06-24FDA Approved: TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION — Original Application (FOSUN PHARMA USA INC)
FDA approved TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION from Fosun Pharma USA Inc as an original ANDA product for lowering intraocular …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Study of LL-BMT1 in Patients With Elevated Intraocular Pressure [Phase 2]
Phase 2 clinical trial of LL-BMT1 in patients with elevated intraocular pressure has completed with results posted.
-
FDA approval · 2022-04-20FDA Approved: BRIMONIDINE TARTRATE/TIMOLOL MALEATE OPHTHALMIC SOLUTION — Original Application (Apotex Corp.)
FDA approved Apotex's brimonidine tartrate/timolol maleate ophthalmic solution as an Original Application generic to lower intraocular press…
-
CLINICAL_TRIALS withdrawal · 2022-04-07Clinical Trial Update: Pilocarpine After Combined Cataract/Trabectome Surgery [Phase 3]
Phase 3 trial of pilocarpine after combined cataract/trabectome surgery was withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT [Phase 4]
Phase 4 clinical trial update comparing latanoprost preserved vs unpreserved on tear film thickness measured by OCT in glaucoma and ocular h…
-
FDA approval · 2022-04-04FDA Approved: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE — Original Application (Sandoz Inc)
FDA approves Sandoz Inc's original ANDA for a fixed-dose combination of brimonidine tartrate and timolol maleate to lower intraocular pressu…
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. [Phase 4]
Phase 4 trial assessing 24-hour efficacy and tolerability of tafluprost-timolol fixed combination without preservatives in glaucomatous or o…
-
CLINICAL_TRIALS trial_result · 2022-03-15Clinical Trial Update: Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl [Phase 4]
A Phase 4 study evaluating switching from prostaglandin monotherapy to omidenepag isopropyl for prostaglandin-associated peri-orbitopathy in…
-
FDA approval · 2022-03-08FDA Approved: LUMIGAN — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Lumigan (bimatoprost) submitted by Allergan, Inc., resulting in an updated label for the pro…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial comparing Bimatoprost SR to selective laser trabeculoplasty in open-angle glaucoma or ocular hypertension has completed with r…
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: Evaluation of Safety and Efficacy of PDP-716 [Phase 3]
Phase 3 clinical trial evaluating PDP-716 for open angle glaucoma and ocular hypertension has completed with results posted in 2022.
-
FDA approval · 2022-01-31FDA Approved: BRIMONIDINE TARTRATE — Original Application (Apotex Corp.)
FDA approved the original application for brimonidine tartrate from Apotex Corp, a generic product used to lower intraocular pressure in gla…
-
FDA approval · 2022-01-28FDA Approved: TAFLUPROST — Original Application (Sandoz Inc)
FDA approves Sandoz's Tafluprost as an original application (ANDA) for generic tafluprost indicated to reduce intraocular pressure in open-a…
-
FDA approval · 2022-01-27FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Original Application (Sagent Pharmaceuticals)
FDA approved the original generic application for dorzolamide hydrochloride from Sagent Pharmaceuticals. The topical solution is used to low…
-
FDA approval · 2022-01-25FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Original Application (Micro Labs Limited)
FDA approved the preservative-free fixed-dose combination of dorzolamide hydrochloride and timolol maleate under Micro Labs Limited's origin…
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial comparing PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) ophthalmic solution to GANFORT in open-angle glaucoma and ocular hyper…
-
FDA approval · 2021-12-13FDA Approved: TIMOPTIC IN OCUDOSE — Original Application (Nordic Pharma, Inc.)
FDA approves Nordic Pharma's TIMOPTIC IN OCUDOSE (timolol maleate) under an original ANDA application.
-
FDA approval · 2021-12-03FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Supplemental Application (Advagen Pharma Ltd.)
FDA approved a supplemental application for dorzolamide hydrochloride submitted by Advagen Pharma Ltd. The action reflects an approved suppl…
-
CLINICAL_TRIALS withdrawal · 2021-11-19Clinical Trial Update: A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial comparing SDP-133 (Sun Pharma) daily with Lumigan in open-angle glaucoma or ocular hypertension was withdrawn.
-
FDA approval · 2021-11-17FDA Approved: TIMOPTIC — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for TIMOPTIC (timolol maleate) submitted by Bausch & Lomb Incorporated.
-
CLINICAL_TRIALS trial_result · 2021-10-11Clinical Trial Update: Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT [Phase 3]
Phase 3 trial evaluating safety and efficacy of OTX-TP in open angle glaucoma and ocular hypertension has completed with results posted.